Avian Influenza

HepaLife's PBS-1 cells for avian influenza vaccine achieve research objective

Published in Medical Patent Week, January 7th, 2007

HepaLife Technologies, Inc., (HPLF) announced confirmation that the company's patented "PBS-1" cells, under development for avian influenza vaccines, are free of pathogens, diseases, bacteria, and potentially harmful viruses.

Pathogen-free cells are critical for the rapid development of cell-culture-based vaccine production to help protect against the spread of influenza viruses among humans, including potentially the high-pathogenicity H5N1 avian flu virus.

"I'm very pleased that independent lab tests have confirmed our PBS-1 cells are pathogen-free. This is especially good news for HepaLife's researchers, who can now confidently accelerate our...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Patent Week

Source: Medical Patent Week (2007-01-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry